Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
Sleep ; 31(1): 79-90, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18220081

ABSTRACT

STUDY OBJECTIVES: To evaluate long-term efficacy and safety of zolpidem extended-release 3 to 7 nights/week for chronic primary insomnia. DESIGN: Multicenter, 25-week, phase IIIb, randomized, double-blind, placebo-controlled, parallel-group. SETTING: Outpatient; visits every 4 weeks. PATIENTS: Aged 18 to 64 years; DSM-IV criteria for chronic primary insomnia; > or =3 months of difficulty initiating or maintaining sleep or experiencing nonrestorative sleep. INTERVENTIONS: Single-dose zolpidem extended-release 12.5 mg (n = 669) or placebo (n = 349), self-administered from a minimum of 3 nights/week to a maximum of 7 nights/week. MEASUREMENTS AND RESULTS: Patient's Global Impression (PGI) and Clinical Global Impression-Improvement (CGI-I) were assessed every 4 weeks up to week 24. Patient Morning Questionnaire (PMQ), recorded daily, assessed subjective sleep measures-sleep onset latency (SOL), total sleep time (TST), number of awakenings (NAW), wake time after sleep onset (WASO), and quality of sleep (QOS)-and next-day functioning. At week 12, PGI, Item 1 (aid to sleep), the primary endpoint, was scored as favorable (i.e., "helped me sleep") by 89.8% of zolpidem patients vs. 51.4% of placebo patients (P < 0.0001, based on rank score) and at week 24 by 92.3% of zolpidem extended-release patients vs. 59.7% of placebo patients. Zolpidem extended-release also was statistically significantly superior to placebo at every time point for PGI (Items 1-4) and CGI-I (P < 0.0001, rank score), TST, WASO, QOS (P < 0.0001), and SOL (P < or = 0.0014); NAW (Months 2-6; P < 0.0001). Sustained improvement (P < 0.0001, all time points) was observed in morning sleepiness and ability to concentrate (P = 0.0014, month 6) with zolpidem extended-release compared with placebo. Most frequent adverse events for zolpidem extended-release were headache, anxiety and somnolence. No rebound effect was observed during the first 3 nights of discontinuation. CONCLUSIONS: These findings establish the efficacy of 3 to 7 nights per week dosing of zolpidem extended-release 12.5 mg for up to 6 months. Treatment provided sustained and significant improvements in sleep onset and maintenance and also improved next-day concentration and morning sleepiness.


Subject(s)
Hypnotics and Sedatives/administration & dosage , Pyridines/administration & dosage , Sleep Initiation and Maintenance Disorders/drug therapy , Adult , Analysis of Variance , Chronic Disease , Delayed-Action Preparations , Double-Blind Method , Drug Administration Schedule , Drug Tolerance , Female , Humans , Hypnotics and Sedatives/adverse effects , Male , Middle Aged , Pyridines/adverse effects , Severity of Illness Index , Surveys and Questionnaires , Zolpidem
2.
Ann Pharm Fr ; 65(4): 268-74, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17652996

ABSTRACT

A variety of molecules with novel mechanisms of action are currently being evaluated for their potential as treatments for sleep disorders. The GABA-A receptor complex remains an important target for hypnotic drugs (eg gaboxadol, indiplon). However, drugs acting through histamine, calcium channels and serotonin receptors may also be of interest for the treatment of insomnia. In the case of the 5HT2A subtype of serotonin receptors, several molecules which improve sleep maintenance and modify sleep architecture by increasing slow wave sleep are currently being tested (eg eplivanserin). Two new drugs with efficacy in excessive sleepiness (modafinil, sodium oxybate) have improved the treatment of this condition. However, the mechanisms of action of these agents are poorly understood. The recent discovery of the hypocretin arousal system in the hypothalamus may aid the identification of additional new drugs. An agonist at receptors for the pineal hormone melatonin is available in some countries (ramelteon) but is currently used only for the treatment of insomnia associated with difficulties of sleep onset. Additional melatonin receptor agonists are being developed and may have potential for treating several conditions including circadian rhythm disorders and depression.


Subject(s)
Arousal/drug effects , Sleep Wake Disorders/drug therapy , Central Nervous System Stimulants/therapeutic use , Circadian Rhythm/drug effects , Circadian Rhythm/physiology , Humans , Melatonin/pharmacology , Melatonin/therapeutic use , Receptors, GABA-A/drug effects , Receptors, GABA-A/physiology , Serotonin Agents/pharmacology , Serotonin Agents/therapeutic use , Sleep Initiation and Maintenance Disorders/drug therapy
3.
Melanoma Res ; 12(4): 343-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12170183

ABSTRACT

Interleukin-1beta converting enzymes (ICEs/caspases) are involved in programmed cell death (apoptosis). This study sought to quantify the caspase-1 level in metastatic malignant melanoma patients and to try to establish a correlation between the level of caspase-1 and different parameters related to this pathology. In addition, we evaluated the possible relationship between the clinical response to biochemotherapy and the caspase-1 level. The serum caspase-1 level was determined in 81 metastatic malignant melanoma patients and 50 normal volunteers using enzyme-linked immunosorbent assay (ELISA). Patients received cisplatin, recombinant interleukin-2 (Proleukin) and alpha-interferon (Roferon A) in two induction cycles, and assessment of clinical response was performed according to World Health Organization (WHO) criteria. The median caspase-1 level in melanoma patients was significantly higher (P = 0.0035) than in control samples. Interestingly, a positive correlation between caspase-1 level and the tumour burden was shown (rs = 0.629, P = 0.009). When the clinical response was taken into consideration, the level of caspase-1 was significantly higher in biochemorefractory patients compared with responding ones (P = 0.04). After treatment, the caspase-1 level remained very high in biochemorefractory patients, while in responding ones no change was observed. Furthermore, a positive correlation between the clinical response and the caspase-1 level was established (rs = 0.404, P = 0.024). In conclusion, we observed an elevated caspase-1 level in metastatic malignant melanoma patients. In addition, the correlations obtained between the caspase-1 level and both the tumour burden and the clinical response to the treatment support the concept that disrupted apoptosis pathways might be involved in the progressive disease of advanced melanoma and/or may confer resistance to treatment.


Subject(s)
Apoptosis , Caspase 1/blood , Drug Resistance, Neoplasm , Melanoma/enzymology , Neoplasm Proteins/blood , Adult , Aged , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/blood , Caspase 1/physiology , Cisplatin/therapeutic use , Combined Modality Therapy , Disease Progression , Female , Humans , Immunologic Factors/therapeutic use , Interferon-alpha/therapeutic use , Interleukin-2/therapeutic use , L-Lactate Dehydrogenase/blood , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Neoplasm Metastasis , Neoplasm Proteins/physiology , Recombinant Proteins/therapeutic use , Treatment Outcome
4.
Melanoma Res ; 10(5): 461-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11095407

ABSTRACT

The transmembrane receptor Fas/APO-1, together with its protein-binding partner (Fas ligand), is a key regulator of programmed cell death and induces apoptosis when it binds Fas ligand (FasL) or soluble Fas ligand (sFasL). However, soluble Fas (sFas) blocks apoptosis by inhibiting binding between Fas and FasL or sFasL. At present, the status of sFas and sFasL in metastatic malignant melanoma remains unknown. This study sought to evaluate the relationship between plasma levels of sFas and/or sFasL and clinical response in 45 metastatic malignant melanoma patients treated by biochemotherapy. sFas and sFasL were measured by specific enzyme-linked immunosorbent assay (ELISA) tests in the sera from patients and 34 healthy donors. Overall, sFas and sFasL levels in patients were significantly higher (P < 0.0001) than in healthy donors. Before the biochemotherapy treatment the sFas level was about the same in biochemorefractory (n = 26) as in responder patients (n = 19). In contrast, the sFasL level was very high only in biochemorefractory patients. At the end of the treatment, in biochemorefractory patients the sFas level was extremely significantly increased (P < 0.0001) and a significant decrease in the plasma levels of sFasL was observed (P = 0.0002). In responder patients, no change in sFas and sFasL was detected. In conclusion, elevated levels of sFas and sFasL might be associated with poor prognosis in advanced melanoma; their possible role in the regulation of apoptosis in influencing the response to biochemotherapy should be further explored.


Subject(s)
Melanoma/blood , Melanoma/secondary , Membrane Glycoproteins/blood , fas Receptor/blood , Adult , Enzyme-Linked Immunosorbent Assay , Fas Ligand Protein , Female , Humans , L-Lactate Dehydrogenase/blood , Male , Melanoma/diagnosis , Melanoma/drug therapy , Middle Aged , Neoplasm Metastasis , Reference Values , Sensitivity and Specificity
5.
Br J Dermatol ; 143(2): 307-12, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10951137

ABSTRACT

BACKGROUND: Impaired regulation of apoptosis is known to be associated with the development of various cancers. Fas receptor (APO-1/CD95) binding to its ligand, Fas-ligand (Fas-L), has been shown to trigger apoptosis in various cell types. OBJECTIVES: In this study, we examined CD95 and Fas-L expression on primary and metastatic melanoma cells from patients to investigate a potential correlation between these measures of apoptosis and different disease stages. PATIENTS AND METHODS: Primary melanoma cells were obtained after surgical resection from 19 patients and metastatic cells from fine-needle aspiration of lymph nodes or palpable subcutaneous lesions in 25 patients. Normal skin cells were obtained at skin biopsy of 10 healthy donors. RESULTS: Flow cytometric analysis revealed that CD95 and Fas-L expression was detected in all the kinds of cell studied. In whole cell suspensions, CD95 expression was significantly higher (P < 0.0001) in normal skin cells than in melanoma cells, whatever the stage studied. By contrast, we observed an increase in Fas-L expression in melanoma cells compared with normal ones. Subsequently, using a double staining method, we studied these measures on HMB45+ cells, a specific marker for melanoma cells, and found that CD95 expression was significantly higher (P = 0.0005) in primary than in metastatic cells while Fas-L expression was significantly increased (P = 0. 0004) in metastatic compared with primary cells. Furthermore, a relationship was found between CD95 or Fas-L expression and Breslow thickness; as primary melanoma thickness progressively increased, the percentage of HMB45+ CD95+ cells decreased while that of HMB45+ Fas-L+ cells concurrently increased. CONCLUSIONS: These results suggest that downregulation of CD95 and upregulation of Fas-L in melanoma might be considered as concomitant with disease progression.


Subject(s)
Antigens, Neoplasm/metabolism , Melanoma/metabolism , Membrane Glycoproteins/metabolism , Skin Neoplasms/metabolism , fas Receptor/metabolism , Apoptosis , Disease Progression , Fas Ligand Protein , Flow Cytometry , Humans , Ligands , Melanoma/pathology , Melanoma/secondary , Neoplasm Proteins/metabolism , Skin Neoplasms/pathology
6.
Cytokines Cell Mol Ther ; 6(3): 135-40, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11140882

ABSTRACT

Interleukin-6 (IL-6) has been shown to support either autocrine or paracrine growth in melanoma, and may prevent programmed cell death in different cell types. We have previously demonstrated that the endogenous IL-6 level is significantly correlated with tumor burden and nonresponse to biochemotherapy in metastatic malignant melanoma patients. In the present study, we investigated the relationship between endogenous IL-6 and apoptosis signal through Fas (APO-1/CD95) receptor expression in 9 responder and 15 refractory patients with metastatic disease treated by biochemotherapy. Before any treatment, double immunostaining demonstrated that 61.5% of the tumor cells were HMB45+CD95+. At day 49 in refractory patients, a significant decrease (p = 0.04) of total Fas expression was observed. Furthermore, a significant reduction (p = 0.032) in the percentage of HMB45+CD95* cells occurred. An 11-fold increase in serum IL-6 level was detected (p < 0.002). This increase was negatively correlated (r = -0.2, p = 0.008) with the decrease in total Fas expression. However, in responding patients, no detectable decrease in Fas expression was observed, while a very low increase in serum IL-6 (2-fold) was detected. These results suggest that the increased endogenous IL-6 level in refractory patients may inhibit apoptosis via modulation of Fas expression. These preliminary results must be interpreted with caution, and further study with a greater number of patients is needed to understand the mechanism by which IL-6 inhibits apoptosis in melanoma.


Subject(s)
Interleukin-6/blood , Melanoma/immunology , fas Receptor/metabolism , Adult , Aged , Antigens, Neoplasm , Apoptosis , Cisplatin/therapeutic use , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Humans , Interleukin-2/therapeutic use , Male , Melanoma/drug therapy , Melanoma/pathology , Melanoma/secondary , Melanoma-Specific Antigens , Middle Aged , Neoplasm Proteins/metabolism , Tumor Necrosis Factor-alpha/metabolism
7.
Int Clin Psychopharmacol ; 14(4): 199-208, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10468312

ABSTRACT

Tiapride is a substituted benzamide with selective dopamine D2 and D3-antagonist properties which appears to have preferential affinity for extra-striatal dopamine receptors. Tiapride is used in the treatment of agitation, aggressiveness and anxiety in the elderly. To define the effects of a single dose of tiapride 100 mg on psychomotor performance and cognitive functions and electroencephalogram (EEG), a randomized, double-blind, three-way crossover, placebo-controlled study using lorazepam 1 mg as a positive control was carried out in 12 elderly individuals (six women and six men, mean age +/- SD: 69 +/- 3 years). A 1-week wash-out interval was allowed between each administration. Psychomotor and cognitive functions were assessed using both objective [EEG, critical flicker fusion, simple reaction time, tapping, body sway, continuous performance task (CPT), digit symbol substitution test, Sternberg memory scanning and a learning memory test using word lists] and subjective (visual analogue scales) measures before and up to 6 h after dosing. Tiapride was devoid of any detrimental or sedative effects on EEG and all of the performance tasks used and did not impair memory compared with-placebo. In contrast, a single dose of lorazepam produced significant deleterious effects on psychomotor performance (decrease in tapping and in sustained attention (CPT) and an increase in reaction time and body sway), and sedative effects on EEG (significant increase in delta and decrease in alpha waves) as well as significant impairment in working memory (Sternberg) and anterograde amnesia (decrease in immediate and delayed free recall) up to 6 h after dosing compared with placebo and tiapride. In conclusion, the present study showed that in contrast to lorazepam 1 mg there is no evidence to suggest that a single dose of tiapride 100 mg has any sedative and amnestic effects in the elderly which may interfere with everyday life activities.


Subject(s)
Antipsychotic Agents/pharmacology , Cognition/drug effects , Electroencephalography/drug effects , Tiapamil Hydrochloride/pharmacology , Aged , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Cross-Over Studies , Double-Blind Method , Female , Flicker Fusion/drug effects , Humans , Learning/drug effects , Male , Memory/drug effects , Psychomotor Performance/drug effects , Reaction Time/drug effects , Tiapamil Hydrochloride/adverse effects , Tiapamil Hydrochloride/pharmacokinetics
8.
Melanoma Res ; 9(2): 181-8, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10380941

ABSTRACT

During recent years it has become clear that the production of most cytokines could play an important role in malignancies. We previously demonstrated that a high endogenous interleukin-6 (IL-6) level is significantly correlated with a high tumour burden and resistance to biochemotherapy in metastatic malignant melanoma patients. However, little is known about the origin of IL-6 and the pattern of IL-6 receptor (IL-6R) expression. In this report, we studied the expression of IL-6R and intracellular IL-6 using flow cytometry in tumour cells provided by fine-needle aspiration of lymph nodes and palpable metastatic lesions from 14 patients refractory to biochemotherapy and six responder patients. Moreover, we established the relationship between these parameters and the serum IL-6 level. Our results demonstrated that, following treatment, the percentage of HMB45-positive (HMB45+) cells expressing functional IL-6R, intracellular IL-6 or both IL-6R and IL-6 significantly decreased in patients refractory to biochemotherapy. In contrast, in responder patients the percentage of HMB45+ cells expressing IL-6R increased and those expressing IL-6 remained stable. Regarding the serum IL-6 level, an 11-fold increase was observed in the patients refractory to biochemotherapy, but only a 1.8-fold increase in the responder patients. In conclusion, in metastatic malignant melanoma patients with a poor prognosis, the endogenous production of IL-6 is concomitant with a decrease in functional IL-6R and intracellular IL-6 expression, suggesting the involvement of an IL-6/IL-6R complex.


Subject(s)
Interleukin-6/metabolism , Melanoma/drug therapy , Melanoma/metabolism , Receptors, Interleukin-6/metabolism , Adult , Aged , Antigens, Neoplasm , CD3 Complex/analysis , Drug Resistance, Neoplasm , Female , Flow Cytometry , Humans , Male , Melanoma-Specific Antigens , Middle Aged , Neoplasm Proteins/analysis
9.
Gene Ther ; 5(8): 1114-21, 1998 Aug.
Article in English | MEDLINE | ID: mdl-10326035

ABSTRACT

We have previously demonstrated that transfected hepatocellular carcinoma cells (Hepa1-6) with one copy (pAGO) and two copies (pYED) of the HSVtk gene, using liposomes, induced cell death of untransfected cells in the presence of ganciclovir (GCV). This phenomenon is called the 'bystander effect'. To determine whether an elevated level of connexin43 increases the bystander effect, we have cotransfected Hepa1-6 cells with a plasmid containing the HSVtk gene driven by the alpha-fetoprotein promoter (pFTK) or pAGO or pYED and connexin43. The results showed that, after GCV treatment, the percentage of growth inhibition was higher (25-30%) in cells cotransfected with HSVtk and connexin43 than in cells transfected only with HSVtk gene. The IC50 of GCV on cells transfected with pFTK/Connexin43 was 17.85-fold lower than cells transfected with pFTK alone. To improve these results, stable connexin43 transduced Hepa1-6 cells were transfected with pFTK followed by GCV treatment. In this case, the cell growth was markedly inhibited as compared with parental cells. Furthermore, we have studied the correlation between the expression of the HSVtk and the connexin43 proteins. Using flow cytometric analysis, scrape loading/dye transfer and immunoblotting assay we found that the cells transfected separately by pAGO, pYED, pFTK and pLTR-Cx43 showed an increase of connexin43 protein. This study indicates that transfecting Hepa1-6 cells with both connexin43 and HSVtk genes up-regulates connexin43 expression which enhances the bystander effect and subsequently tumor cell death.


Subject(s)
Carcinoma, Hepatocellular/therapy , Connexin 43/genetics , Genetic Therapy/methods , Liver Neoplasms/therapy , Simplexvirus/enzymology , Thymidine Kinase/genetics , Animals , Antiviral Agents/therapeutic use , Cell Communication , Combined Modality Therapy , Flow Cytometry , Ganciclovir/therapeutic use , Gap Junctions , Gene Expression Regulation , Liposomes , Mice , Microscopy, Fluorescence , Transfection , Tumor Cells, Cultured
10.
J Immunol Methods ; 204(1): 51-6, 1997 May 12.
Article in English | MEDLINE | ID: mdl-9202709

ABSTRACT

A flow cytometric method has been developed for the rapid analysis of lacZ transduced cells. The method described is based on an indirect immunofluorescence staining procedure using a monoclonal antibody which binds specifically to beta-galactosidase from E. coli and to beta-galactosidase fusion proteins. This technique was used for the quantification in vitro as well as in vivo of beta-galactosidase expression in B16 melanoma cells. The described method is appropriate for a variety of cell types (species, lineage), is simple, quantitative, reliable, rapid and applicable to all constructs containing the lacZ selectable markers. It should prove to be very helpful (1) for the quantification of cells expressing the lacZ reporter gene and (2) for studying gene regulation, including transfection modality, promoter efficacy, enhancer activity, and other regulatory factors.


Subject(s)
Bacterial Proteins/analysis , Flow Cytometry/methods , beta-Galactosidase/analysis , Bacterial Proteins/genetics , Fluorescent Antibody Technique, Indirect , Transfection , Tumor Cells, Cultured , beta-Galactosidase/genetics
11.
Semin Oncol ; 24(1 Suppl 2): S2-38-S2-40, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9045335

ABSTRACT

The clinical activity and toxicity of the triple combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), cyclophosphamide, and cisplatin was assessed in both previously treated and untreated women with advanced ovarian carcinoma. Paclitaxel 175 mg/m2 was administered over 3 hours following standard premedication (prednisolone, dexchlorpheniramine, and cimetidine). Cisplatin 80 mg/m2 and cyclophosphamide 600 mg/m2 were given 6 to 12 hours after paclitaxel. Treatment was given at 3-week intervals for six cycles. Twenty-seven patients entered the study; 23 were evaluable for toxicity and 17 for response. Paclitaxel appeared to add additional efficacy to the standard cisplatin/cyclophosphamide regimen. Both the overall and complete remission rates were very high (88% and 70%, respectively), and histologically confirmed complete remissions exceeded 60%. Longer follow-up is needed to determine the duration of these responses. The primary toxicities included leukoneutropenia, peripheral neuropathy, asthenia, and alopecia. Only two of 23 patients withdrew because of toxicity, however, and only two treatment cycles were complicated by neutropenic fever requiring intravenous antibiotics. No life-threatening toxicities were encountered, although the peripheral neuropathy was poorly and slowly reversible and may have a significant impact on the patients' quality of life.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Paclitaxel/administration & dosage , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Feasibility Studies , Female , Humans , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/pathology , Remission Induction
12.
Cancer J Sci Am ; 3 Suppl 1: S16-21, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9457388

ABSTRACT

PURPOSE: This article investigates the safety and efficacy of a simple cisplatin-based biochemotherapy regimen, containing single-agent cisplatin plus recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN-alpha), in the treatment of metastatic melanoma. PATIENTS AND METHODS: Between December 1990 and April 1997, 129 patients were treated with cisplatin (100 mg/m2, day 0) plus continuous intravenous infusion rIL-2 (18 MIU/m2/day, days 3-6 and days 17-21) and subcutaneous rIFN-alpha (9 MIU three times per week) plus or minus tamoxifen (160 mg/day) on three different protocols. Tumor response, disease-free survival, and overall survival were evaluated for all evaluable patients (N = 127). RESULTS: The overall response rate was 49%, and 10% of patients achieved a complete response. Responses were observed at all sites of metastases. In one case, a patient with a large cutaneous inguinal mass experienced a dramatic regression of that lesion within 1 month. The median disease-free survival was 5 months, and median overall survival was 11 months. Patients who responded had a significant survival advantage over nonresponders, and patients who achieved a complete response had a significant survival advantage over patients with a partial response. Toxicities were manageable and reversible upon discontinuation of therapy. CONCLUSION: The response rates achieved with this simple biochemotherapy regimen are comparable to those for other cisplatin-based biochemotherapy regimens, which use more complex multiagent chemotherapy regimens. We found no added clinical benefit from the addition of tamoxifen to cisplatin.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Immunotherapy , Interleukin-2/administration & dosage , Melanoma/therapy , Adolescent , Adult , Aged , Cisplatin/administration & dosage , Combined Modality Therapy , Female , Humans , Injections, Subcutaneous , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Melanoma/mortality , Middle Aged , Recombinant Proteins/administration & dosage , Survival Rate , Tamoxifen/administration & dosage , Treatment Outcome
13.
Semin Oncol ; 23(6 Suppl 15): 5-8, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8996589

ABSTRACT

In this phase I/II study, we assessed the impact of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of advanced ovarian carcinoma combined with the standard regimen cisplatin/cyclophosphamide given as follows: paclitaxel 175 mg/m2 (over 3 hours perfusion with standard premedication), cisplatin 80 mg/m2 (6 to 12 hours after paclitaxel), and cyclophosphamide 400 mg/m2. From February 1994 to January 1996, 27 patients (median age, 55 years; age range, 35 to 74 years) were entered into the study. Eight patients had distant metastases and 19 had early locoregional disease (stage III, 18 patients; stage IC, one patient). Twenty-two patients had undergone prior surgery (simple biopsy, six patients; optimally debulked, nine patients; suboptimally debulked, seven patients). Twenty-one patients had received no prior chemotherapy and six were previously treated with at least one platinum-based regimen. A maximum of six courses of paclitaxel/cisplatin/cyclophosphamide were given every 21 days. Twenty-three patients were evaluable for toxicity: neutropenia (World Health Organization grade 3/4), 91% of patients; thrombopenia (World Health Organization grade 3/4), 13% of patients; two episodes of neutropenia with fever; and neurotoxicity grade 3, 17% of patients. Alopecia grade 3 was reported in all patients. No hypersensitivity reactions and no cardiac toxicity was observed. Among 17 patients evaluable for response (patients with stage IV disease or stage III suboptimally debulked), 12 (70%) clinical complete responses (CRs) and three (18%) partial responses were observed. Among the 12 patients with CRs, 10 underwent second-look laparotomy and seven of them (70%) achieved a pathologic CR. In the group of 11 chemotherapy-naive patients evaluable for response, eight (72%) achieved a CR and three (28%) achieved a partial response. This combination seems to be safe, with very acceptable toxicity, and also seems to be highly active in the treatment of patients with advanced ovarian carcinoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Adult , Aged , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Drug Administration Schedule , Female , Humans , Middle Aged , Paclitaxel/administration & dosage
14.
Cancer Gene Ther ; 3(6): 385-92, 1996.
Article in English | MEDLINE | ID: mdl-8988841

ABSTRACT

In this study, we investigated whether the regulation and the copy number of the herpes simplex virus thymidine kinase (HSVtk) gene increased the sensitization to ganciclovir (GCV) of glioma cell lines (Rat C6 and human U118-MG) using liposome-mediated gene transfer. Three recombinant plasmids carrying the HSVtk gene driven by the thymidine kinase promoter in single (pAGo) and double copy (pYED) or by the human cytomegalovirus promoter (pCMVtk) were used for the transfection. The DNA delivery was optimized by screening a panel of cationic liposomes using Lac-Z and luciferase as reporter genes. The efficiency of transfection reached 33% to 36% in vitro but only 18.6% in vivo after an intratumoral injection of DNA-liposome complexes. Moreover, after transfection of the three plasmids, the cell-killing effect of GCV was evaluated. A significant enhancement (four- to fivefold) of the cell sensitivity to GCV was shown in pCMVtk and pYED as compared with pAGo-transfected cells in both cell lines. According to the plasmid, the effect of the HSVtk/GCV system was confirmed by in vivo experiments and was objectified by a higher tumor weight reduction with pCMVtk (49%) than pAGo (27%). From these results, we conclude that (1) the gene transfer can be achieved by cationic liposomes both in vitro and in vivo and that (2) using this type of vector, the antitumor effect of the HSVtk/GCV system could be potentiated by the up-regulation of HSVtk gene duplication.


Subject(s)
Ganciclovir/pharmacology , Gene Transfer Techniques , Glioblastoma/metabolism , Liposomes/metabolism , Phosphatidylethanolamines/metabolism , Thymidine Kinase/genetics , Animals , Cell Survival/drug effects , Disease Models, Animal , Flow Cytometry , Gene Expression Regulation/genetics , Genes, Reporter/genetics , Genetic Therapy , Humans , Neoplasms, Experimental/metabolism , Plasmids/genetics , Rats , Simplexvirus/enzymology , Thymidine Kinase/metabolism , Transfection/genetics , Tumor Cells, Cultured , beta-Galactosidase/genetics , beta-Galactosidase/metabolism
15.
Presse Med ; 25(35): 1690-7, 1996 Nov 16.
Article in French | MEDLINE | ID: mdl-8977581

ABSTRACT

Prognosis in metastatic malignant melanoma is poor because of chemo and radiotherapy resistance. However, some drugs, such as dacarbazine, cisplatinum or fotemustine, a new nitrosourea, have produced a response rate of more than 20%. Combining these drugs increases response rate to 30-40%. Immunotherapy by interferon-alpha 2 shows about 15-20% response rate but interleukin-2 would be more effective especially in combination with cisplatinum and interferon-alpha 2 with 50% response and long survival after cessation of treatment.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Immunotherapy , Melanoma/therapy , Combined Modality Therapy , Humans , Melanoma/drug therapy , Melanoma/secondary
16.
Gene Ther ; 3(10): 913-8, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8908505

ABSTRACT

The antiviral drug ganciclovir (GCV) is toxic for mammalian cells transfected with the herpes simplex virus thymidine kinase (HSVtk) gene. To improve the results obtained by our group previously on nonviral transfection of tumor cells, we have examined here in vitro virus-free transfection of murine B16 melanoma cells via lipofectamine-nucleic acid complexes carrying either HSVtk gene transcripts or plasmid DNAs containing single and double copies of the HSVtk gene. The HSVtk gene transcripts as well as plasmids containing the HSVtk gene(s) rendered cells sensitive to GCV treatment. Tumor sensitivity to GCV conferred by the HSVtk gene transcripts was of the same level as the sensitivity conferred by plasmid DNAs containing a single copy of the HSVtk gene. However, when the plasmids containing double copies of the HSVtk gene were used, sensitivity to low GCV concentrations increased dramatically. One could appreciate this finding as an essential advantage of the plasmids containing double copies of the HSVtk gene since it allows use of the GCV concentration range which is common in clinical applications.


Subject(s)
Antiviral Agents/toxicity , DNA, Viral , Ganciclovir/toxicity , Melanoma, Experimental , RNA, Viral , Simplexvirus/enzymology , Thymidine Kinase/genetics , Animals , Cell Survival , Drug Carriers , Gene Dosage , Humans , Liposomes , Mice , Plasmids , Transfection , Tumor Cells, Cultured
17.
Clin Cancer Res ; 2(8): 1405-9, 1996 Aug.
Article in English | MEDLINE | ID: mdl-9816314

ABSTRACT

The involvement of interleukin (IL-) 6 in malignant disease has been investigated in a variety of different malignancies. To evaluate whether serum IL-6 is a useful disease marker in metastatic malignant melanoma (MMM), we studied the time course of endogenous IL-6 secretion in 41 patients treated with cisplatinum, IL-2, and IFN-alpha. Furthermore, the relationship of endogenous IL-6 concentrations to the tumor burden and/or the clinical response was also evaluated. The baseline serum IL-6 levels were significantly higher in patients with MMM than in the control group (P = 0.002). When tumor burden was taken into consideration, we found that IL-6 levels were higher in patients with high tumor burden than in patients with low tumor burden. During treatment in the whole patient population, a higher serum IL-6 level was observed in nonresponding as compared to responding patients at days 7 (P = 0.0005), 21 (P = 0.002), and 35 (P = 0.009). The follow-up of serum IL-6 in patients with MMM according to the tumor burden and clinical response demonstrated that: (a) IL-6 levels were significantly higher at days 7 and 21 in patients with high tumor burden as compared to those with low tumor burden; and (b) IL-6 levels remain significantly higher in nonresponding patients as compared to responding patients regardless of the tumor burden. From these results, we can conclude that endogenous IL-6 may play a role in the failure of IL-2 therapy in such patients, since the very early IL-6 increase is correlated with the tumor mass and nonresponse to biochemotherapy. Therefore, it seems that the early detection of endogenous IL-6 may represent valuable information for monitoring the response to biochemotherapy in patients with MMM.


Subject(s)
Interleukin-6/blood , Melanoma/blood , Melanoma/secondary , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Melanoma/drug therapy , Middle Aged
18.
Gene Ther ; 3(6): 483-90, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8789797

ABSTRACT

Many approaches exist for hepatic gene delivery, including viral vectors and non-viral vectors. In this study, we tested a panel of liposomes to transfer pAGO, a plasmid containing one copy of herpes simplex virus (HSVtk) gene, and pYED11, a plasmid containing two copies of the HSVtk gene, into a murine hepatocarcinoma cell line (Hepa 1-6) and a human hepatocarcinoma cell line (Hep-G2). The efficiency of gene delivery and expression was characterized by beta-galactosidase staining, flow cytometric analysis and quantitative lacZ activity. Different combinations of liposomes and DNA and the ratio of the concentration of liposome to DNA were tested. The efficient transfer was shown with DOTAP followed by transfectam and lipofectamine. Under these conditions, we tested the cytotoxicity of ganciclovir (GCV) exposure on Hepa 1-6 and Hep-G2 transfected separately with liposome-pAGO and liposome-pYED11 complexes. This study demonstrates the in vitro efficacy of each liposome tested to transduce the HSVtk gene into hepatocarcinoma cell lines. The transfer of two copies of the HSVtk gene rendered cells 1.5 times more sensitive to GCV than cells transduced by pAGO as compared to controls. This was achieved most efficiently by the DOTAP-pYED11 complex. Thus, pYED11 may be considered as an alternative to pAGO as a gene transfer vector.


Subject(s)
Antiviral Agents/toxicity , Ganciclovir/toxicity , Plasmids , Simplexvirus/genetics , Thymidine Kinase/biosynthesis , Transfection/methods , Animals , Carcinoma, Hepatocellular , Cell Line , Cell Survival/drug effects , Humans , Liposomes , Liver Neoplasms , Liver Neoplasms, Experimental , Mice , Polymerase Chain Reaction , Recombinant Proteins/biosynthesis , Simplexvirus/enzymology , Thymidine Kinase/genetics , Tumor Cells, Cultured , beta-Galactosidase/biosynthesis
19.
Clin Diagn Lab Immunol ; 3(3): 315-20, 1996 May.
Article in English | MEDLINE | ID: mdl-8705676

ABSTRACT

There is a substantial interest in the role of antineutrophil antibodies since Fc gamma receptors (Fc gamma Rs) have been identified as the target for the majority of such autoantibodies. Antineutrophil antibodies have long been detected by an indirect immunofluorescence technique. Following optimization of the flow cytometric method of detection, we developed three enzyme-linked immunosorbent assays (ELISAs), each specific for autoantibodies against one of the three classes of human Fc gamma R. Fc gamma RI and Fc gamma RII were purified from cultured cells, and Fc gamma RIII was produced as a recombinant molecule. These were then used as capture agents in the respective ELISAs. When applied in parallel to a sizeable group of patients with primary Sjögren's syndrome, both methods established that anti-Fc gamma R autoantibodies were heterogeneous. This finding indicates that different populations of partly cross-reactive antibodies are detectable by these two methods.


Subject(s)
Enzyme-Linked Immunosorbent Assay , Receptors, IgG/immunology , Autoantibodies/analysis , Flow Cytometry , Humans
20.
Eur J Cancer ; 32A(4): 691-5, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8695274

ABSTRACT

The aim of the study was to use a virus-free system to transfer the Herpes Simplex Virus-thymidine kinase (HSV-TK) gene in mice bearing melanoma tumours. B16 F1 murine melanoma cells were injected subcutaneously. On days 11 and 14, an intratumoral injection of either naked plasmid containing the HSV-TK gene (pAG0) or pAG0-lipofectamine complexes was given. Ganciclovir (120 mg/kg/day) was given for 5 days starting on day 14. Tumour weight reduction (40-50%) was observed in treated animals versus different control groups. Moreover, histopathological analysis on tumours showed large areas of cavitary necrosis (85%) in treated groups compared to controls (10%). Using a simple and safe method, the results presented here demonstrated that virus-free mediated delivery of the HSV-TK gene is efficient in vivo in murine malignant melanoma.


Subject(s)
Gene Transfer Techniques , Genes, Viral/genetics , Melanoma, Experimental/therapy , Simplexvirus/genetics , Thymidine Kinase/genetics , Viral Structural Proteins/genetics , Animals , Genetic Vectors , Male , Melanoma, Experimental/genetics , Mice , Mice, Inbred C57BL , Thymidine Kinase/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...